4 completed, 2 unknown, 1 recruiting. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Unknown 2, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Primary Myelofibrosis (PMF): new trials by email Literature Review of Primary Myelofibrosis (PMF) trials Research Report on Primary Myelofibrosis (PMF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis Ropeginterferon alfa-2b (BESREMi®) - Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) | Phase 2 | Recruiting | The University of Hong Kong | 20 | 2025-03-01 | 2025-06-11 |
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis KRT-232, TL-895 - Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Phase 2 | Unknown | Kartos Therapeutics, Inc. | 52 | 2021-04-13 | 2022-05-09 |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis PXS-5505 - Myelofibrosis, Primary Myelofibrosis (PMF) | Phase 1 / Phase 2 | Completed | Syntara | 43 | 2021-02-18 | 2026-08-04 |
| Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis Jaktinib hydrochloride tablets - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 51 | 2020-01-07 | 2023-04-20 |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF) | Phase 2 / Phase 3 | Unknown | Kartos Therapeutics, Inc. | 385 | 2019-01-15 | 2023-04-28 |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Bomedemstat - Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 1 / Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 90 | 2017-07-18 | 2024-01-10 |
| Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) MMB - Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis | Phase 2 | Completed | Sierra Oncology LLC - a GSK company | 41 | 2016-01-29 | 2023-06-18 |
Bone Marrow Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Myeloproliferative Disorders (7)
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (2) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (1) · bomedemstat (1)
Kartos Therapeutics, Inc. (2) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (1) · Sierra Oncology LLC - a GSK company (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Syntara (1) · The University of Hong Kong (1)
United States (5) · Australia (3) · Bulgaria (2) · Canada (2) · Germany (2) · Hong Kong (2) · Italy (2) · Mexico (2) · Poland (2) · Russia (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Belarus (1)
Harinder Gill, MD (1) · Jana Baskar, MBBS MMedSc MBA (1) · Jie Jin, MD (1)
PMID 39516087, PMID 40241543, PMID 41758981, PMID 42054549
2018 (1)